Impact of a Switch From Ciprofloxacin to Ceftriaxone Prophylaxis on Infectious Complications After Transrectal Ultrasound-Guided Biopsy of the Prostate.

Autor: Mendo-Lopez R; Department of Infectious Diseases, University Hospitals, Cleveland, Ohio, USA.; Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA., Lengu I; Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Department of Urology, The MetroHealth System, Cleveland, Ohio, USA., Nguyen C; Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Department of Urology, The MetroHealth System, Cleveland, Ohio, USA., Wilson BM; Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Geriatric Research, Education and Clinical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA., Donskey CJ; Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Geriatric Research, Education and Clinical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA., Hecker MT; Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Department of Infectious Diseases, The MetroHealth System, Cleveland, Ohio, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jul 15; Vol. 11 (7), pp. ofae360. Date of Electronic Publication: 2024 Jul 15 (Print Publication: 2024).
DOI: 10.1093/ofid/ofae360
Abstrakt: In a 12-year single-center quasi-experimental study, a switch from ciprofloxacin to ceftriaxone prophylaxis for transrectal ultrasound-guided prostate biopsy procedures was associated with a significant reduction in 30-day postprocedure urinary tract infection, urinary tract infection-related hospitalizations, antibiotic prescriptions, and isolation of fluoroquinolone-resistant organisms from urine or blood cultures.
Competing Interests: Potential conflicts of interest. C. J. D. has received research funding from Clorox and Pfizer. All other authors report no potential conflicts.
(Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje